Next Article in Journal
The Toxicity of Protein Aggregates: New Insights into the Mechanisms
Next Article in Special Issue
Determinants of COVID-19 Disease Severity–Lessons from Primary and Secondary Immune Disorders including Cancer
Previous Article in Journal
Autophagy in Cancer Progression and Therapeutics
Previous Article in Special Issue
Prenatal and Neonatal Pulmonary Thrombosis as a Potential Complication of SARS-CoV-2 Infection in Late Pregnancy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 9
10.3390/ijms24097975
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019

by
Hideo Wada
1,*,
Katsuya Shiraki
1,
Hideto Shimpo
2,
Motomu Shimaoka
3,
Toshiaki Iba
4 and
Katsue Suzuki-Inoue
5
1
Department of General and Laboratory Medicine, Mie Prefectural General Medical Center, Yokkaichi 5450-132, Japan
2
Mie Prefectural General Medical Center, Yokkaichi 5450-132, Japan
3
Department of Molecular Pathobiology and Cell Adhesion Biology, Mie University Graduate School of Medicine, Tsu 514-0001, Japan
4
Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo 113-8431, Japan
5
Department of Clinical and Laboratory Medicine, Yamanashi Medical University, Yamanashi 409-3821, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(9), 7975; https://doi.org/10.3390/ijms24097975
Submission received: 7 April 2023 / Revised: 26 April 2023 / Accepted: 26 April 2023 / Published: 28 April 2023
(This article belongs to the Special Issue COVID-19 Coagulopathy: Advances on Pathophysiology and Therapies)
Browse Figures
Review Reports Versions Notes

Abstract

:
Coronavirus disease 2019 (COVID-19) has spread, with thrombotic complications being increasingly frequently reported. Although thrombosis is frequently complicated in septic patients, there are some differences in the thrombosis noted with COVID-19 and that noted with bacterial infections. The incidence (6–26%) of thrombosis varied among reports in patients with COVID-19; the incidences of venous thromboembolism and acute arterial thrombosis were 4.8–21.0% and 0.7–3.7%, respectively. Although disseminated intravascular coagulation (DIC) is frequently associated with bacterial infections, a few cases of DIC have been reported in association with COVID-19. Fibrin-related markers, such as D-dimer levels, are extremely high in bacterial infections, whereas soluble C-type lectin-like receptor 2 (sCLEC-2) levels are high in COVID-19, suggesting that hypercoagulable and hyperfibrinolytic states are predominant in bacterial infections, whereas hypercoagulable and hypofibrinolytic states with platelet activation are predominant in COVID-19. Marked platelet activation, hypercoagulability and hypofibrinolytic states may cause thrombosis in patients with COVID-19.

1. Introduction

Coronavirus disease 2019 (COVID-19) has spread worldwide from China [1,2], resulting in a pandemic [3]. It was previously reported that approximately 2% of patients with COVID-19 died, and 5–10% developed severe and life-threatening acute respiratory distress syndrome (ARDS) [4,5,6], with many more patients developing COVID-19 developing mild or moderate illness [7,8]. Following the appearance of the omicron variants of COVID-19 [9], the mortality rate was reduced, but the incidence of infections markedly increased, resulting in a relative increase in deaths. Therefore the management of complications of COVID-19 has become increasingly important.

2. Macrothrombotic Complications

The relationship between COVID-19 and thrombosis including venous thromboembolism (VTE) [10], such as pulmonary embolism (PE), and deep vein thrombosis (DVT) and arterial thrombosis, such as acute cerebral infarction (ACI) [11] and acute coronary syndrome (ACS) [12], has attracted attention [13]. On the other hand, many reports on thrombotic complications, such as disseminated intravascular coagulation (DIC) [14] and thrombotic microangiopathy (TMA) [15] have been previously reported in severe sepsis due to bacterial infection. A soluble C-type lectin-like receptor 2 (sCLEC-2) assay has been recently developed as a biomarker for platelet activation [16,17,18].
We herein review, based on a large number of reports, the mechanism underlying the development of thrombosis in COVID-19, which differs from that in bacterial infection.

3. Incidence of Macrothrombotic Complications in COVID-19

There have been many reports on macrothrombosis, such as VTE, ACS and ACI, in general, and the incidence of all thrombosis has varied substantially (6–26%) among patients with COVID-19 [19] (Table 1).

3.1. VTE

There have been many systematic reviews and meta-analyses concerning VTE [10,19,20,21], and the incidence of VTE, including DVT with PE and DVT, has been reported to vary in COVID-19. VTE was reportedly found more frequently in patients who were admitted to the intensive-care unit (ICU) than in those not admitted to the ICU. More than half of COVID-19 patients with PE (57.6%) lacked DVT [20], suggesting that some cases of PE might be caused by vascular injury instead of embolism. The incidence of VTE was higher when assessed according to screening or prospective studies [10] and postmortem studies [21] than in retrospective studies. These findings suggest that the incidence of VTE is high but varies depending on the incidence and severity of COVID-19, the age and race of patients, and the details of hospitalization and prophylaxis.

3.2. Arterial Thrombosis

The incidence of arterial thrombosis was low (0.7–3.7%) in overall patients [20,21] and 5% among ICU admissions [21]. The frequency of ACS in patients with COVID-19 was 1.0% in overall patients and 6.0–33.0% in cases of severe disease [12,22]. A review of cardiac autopsy cases of COVID-19 found that the most common comorbidities were coronary artery disease (33%) and acute ischemia (8%) [23]. A higher mortality rate among patients with COVID-19 and ST-segment elevation myocardial infarction (STEMI) was noted in comparison to previous studies, with reported concerns being late presentation due to fear of infection, delayed care time, and poor resource allocation [24].
On the neuroimaging of COVID-19 patients, especially critically ill patients, 3.4% of patients showed COVID-19-related neuroimaging findings [25,26], such as white matter abnormalities, followed by acute/subacute ischemic infarction and encephalopathy. The incidence of ACI in patients with COVID-19 is low (0.4–1.3%) [11,26,27,28]. The risk factors for ACS and ACI in patients with COVID-19 include old age, hypertension, diabetes mellitus, coronary artery disease, and severe infection [11,28]. Accurately diagnosing arterial thrombosis is difficult in COVID-19 patients with critical illnesses and there are no routine markers for ACI (such as D-dimer for VTE), which suggests that the true incidence of arterial thrombosis may be increased in COVID-19.
Table
Table 1. Pooled incidence and thromboembolism in patients with COVID-19 infections.
Table 1. Pooled incidence and thromboembolism in patients with COVID-19 infections.
ICU+Non-ICUICUNon-ICUJapan
Pooled incidence (%)
TH6–26 [19]――1.86 [22]
PE7.1–16.5 [10,20,21]19.0–24.7 [20,21]10.5–19.0 [20,21]0.5 [22]
DVT12.1–20.0 [10,20,21]28.0 [21]―0.7 [22]
VTE17.0–21.0 [10,21]4.8–31.0 [10,19,21]1.5–46.1 [10,19]1.2 [22]
ACI0.4–1.3 [11,22,29,30]――0.4 [22]
ACS1.0 [12]6–33 [23]―0.1 [22]
TH, thrombosis; PE, pulmonary embolism; DVT, deep vein thrombosis; TE, thromboembolism; ACI, acute cerebral infarction; ACS. Acute coronary thrombosis, DIC, disseminated intravascular coagulation; COVID-19; coronavirus disease 2019; ICU, intensive-care unit; Reference [10] Jiménez D et al.: 48 studies with 18,093 patients; [11] Nannoni S et al.: 61 studies with 108,571 patients; [12] Zhao YH et al.: 2277 articles with 108,571 patients; [19] Cheng NM et al.: 68 studies; [20] Suh YJ et al.; 27 studies with 3342 patients; [21] Malas MB et al.: 42 studies with 8271 patients; [22] Peiris S et al.: 63 studies; [23] Roshdy A et al.: 316 cases; [26] Kim PH et al.: 17 studies with 1394; [27] Horiuchi H et al.: one questionnaire with 5807 patients; [28] Qureshi AI et al.: 8163 patients; [29] Xiao, D. et al.: systemic review. [30] Pepera, G. et al.; systemic review.

3.3. Mortality

The pooled mortality rate among patients with all types of thrombosis was 23%, while that among patients without any types of thrombosis was 13%. The pooled odds of mortality were 74% higher among patients who developed thrombosis than among those who did not [21]. A systematic review of reports on COVID-19 demonstrated that thrombosis increased the risk of mortality by 161% and the risk of a critical status by 190% [29]. In addition, preexisting cerebrovascular diseases (CVDs) were linked to poor outcomes and an increased risk of death in patients with COVID-19 [30].

3.4. After Discharge

The incidence of events in patients with COVID-19 after discharge was 1.55% for VTE, 0.45% for acute CVD, 0.49% for ACS, 0.77% for other arterial thromboses and 1.73% for major bleeding [31]. In an analysis of patients with and without COVID-19, the incidence of ACI was 1.3% in those with COVID-19 and 1.0% in those without COVID-19, suggesting that the risk of thrombosis continues after discharge and that the management of comorbidities is important for patients with COVID-19. ACI usually occurs in the presence of other cardiovascular risk factors and is associated with a twofold increase in the risk of long hospitalization or death in patients with COVID-19 [28].

3.5. Asia including Japan

The incidence of acute CVD in patients with COVID-19 was shown to be higher in Asia (3.1%) than in Europe (1.1%) and North America (1.1%) [11]. A questionnaire on COVID-19-related thrombosis in 6202 patients hospitalized in Japan showed that thrombotic events occurred in 1.86% of the 5807 patients with available data including symptomatic ACI (0.4%), AMI (0.1%), DVT (0.7%), PE (0.5%), and other thrombotic events (0.4%) [27], suggesting that the frequency of VTE is low in Japan due to the low incidence and severity of COVID-19 and sufficient prophylaxis with heparin.

3.6. Variety of Severity and Complications of Thrombosis in COVID-19

There are large differences in severity or mortality among the COVID-19 variants. Furthermore, an increased number of patients causes an increase in severe patients with COVID-19. The level of the medical system, such as bed numbers for COVID-19, quality of ICU, medical insurance and medication, can decrease mortality or thrombotic complications. Although high mortality was observed in 2019, low mortality due to COVID-19 was observed in 2023. As many factors affect mortality or complications of thrombosis in patients with COVID-19, the evaluation of thrombosis in COVID-19 should be carefully performed (Figure 1).

4. Microangiopathy as DIC and TMA in COVID-19 and Other Infections

4.1. DIC

Although the relationship between DIC and COVID-19 has sometimes been reviewed [32], few systematic reviews have been conducted and the incidence of typical DIC in patients with COVID-19 was shown to be very low [33]. However, it has been generally reported that DIC is frequently associated with patients with other infectious diseases, and the incidence of DIC in other infectious diseases suspected to be bacterial infections is 20–70% [34,35], considering that the incidence of complications with DIC is higher in patients with bacterial infections than in those with COVID-19. The outcome of DIC in septic patients is extremely low [14]. There have been many systematic reviews and studies based on big data of the effects of DIC or sepsis treatments [36,37]. In a recent report that compared COVID-19 to bacterial infection, the mortality rate was 17.0% in patients with other pneumonia, 16.7% in patients with sepsis, and 4.3% in patients with COVID-19, suggesting that the mortality rate due to sepsis is higher than that due to COVID-19 [36]. In addition, thrombosis such as VTE, ACI or ACS is not frequently detected in patients with bacterial infection [38]. There are many differences between septic DIC and COVID-19 coagulopathy. In particular, a clot waveform analysis (CWA) [39] of activated partial thromboplastin time (APTT) showed a large difference between the two diseases. Significant prolongation of the peak time and a marked reduction in the peak height of CWA-APTT were observed in patients with overt DIC [40], whereas moderate prolongation of the peak time and a significant increase in the peak height of CWA-APTT were observed in patients with COVID-19 coagulopathy [41]. Based on these findings, a markedly increased peak height suggests hypercoagulability, while a markedly decreased peak height suggests hypocoagulability (Figure 2). These differences may be caused by hypofibrinogenemia and hyperfibrinolysis in overt DIC and hypercoagulability induced by thrombin burst and hypofibrinolysis in COVID-19 coagulopathy.

4.2. TMA

The association with TMA in patients with COVID-19 has been reviewed [42] and several reports described TMA in patients with COVID-19 [43], with the frequency of TMA being reported to be 1.0–20% and the outcome of TMA varying but quite poor [15]. TMA involves Shiga toxin-producing Escherichia coli (STEC)-hemolytic uremic syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), atypical HUS and secondary HUS [15]. Acquired TTP is caused by the inhibitor for a disintegrin-like and metalloproteinase with thrombospondin type 1 motifs 13 (ADAMTS13) and aHUS is mainly caused by an hereditary abnormality of compliment regulation.
As ADAMTS-13 activity and the complement system are not usually examined, TTP and aHUS may not usually be diagnosed in general hospitals. However, decreased ADAMTS-13 activity and elevated C5b-9 levels have been reported in patients with COVID-19 [41,44,45]. The low incidence of TMA may be due to the lack of diagnostic biomarkers for TMA in clinical use. Elevated sCLEC-2 levels suggest that critically ill patients with COVID-19 have some degree of microangiopathy [46]. A marked elevation of sCLEC-2 levels was also reported in patients with TMA [17], suggesting the marked activation of platelets in patients with COVID-19 as well as in patients with TMA. Many critically ill patients with COVID-19 are also associated with thrombocytopenia, anemia and organ failure, suggesting that these patients met the diagnostic criteria of TMA [47] and necessitating further investigation for TMA in patients with COVID-19. COVID-19 complicated with TMA is expected to increase in frequency going forward.

5. Biomarkers for Thrombosis in COVID-19

5.1. Routine Biomarkers

Although conventional PT and APTT are hemostatic markers and cannot show hypercoagulability and thrombotic risk, CWA-APTT and a small amount of TF-induced FIX activation assay (sTF/FIXa) can show hypercoagulability [39]. D-dimer values have been reported to be useful biomarkers with a high sensitivity for thrombosis in patients with COVID-19 and are correlated with the severity of COVID-19 [19,20] (Table 2). Although elevated D-dimer levels are a well-known risk factor for thrombosis, the D-dimer cutoff level is low in COVID-19 [48]. Although D-dimer is useful for the exclusion of VTE in patients with COVID-19, it may not be useful for the diagnosis of VTE in patients with COVID-19 [15,19,20]. D-dimer levels were reported to be significantly higher in patients with other pneumonia and sepsis due to bacterial infections than in patients with COVID-19, whereas there was no significant difference in D-dimer levels between patients with unidentified clinical syndrome and those with COVID-19 [14,15,46].
Platelet counts were extremely low in patients with sepsis and other pneumonia due to bacterial infection, especially DIC or pre-DIC, but only moderately low in COVID-19 patients with critical illness [14,15,46]. As multiple viruses interfere with hematopoiesis, thrombocytopenia is a common phenomenon in various viral infections including COVID-19 [49]. However, thrombocytopenia is suggested to be associated with increased platelet consumption and destruction in COVID-19. The prothrombin time (PT) and APTT were significantly prolonged in septic patients with DIC but not in patients with COVID-19 [14,15,46]. Therefore, DIC and sepsis-induced coagulopathy are generally diagnosed using a scoring system based on PT, platelet counts and fibrin-related products, such as D-dimer levels [50,51,52]. Fibrinogen levels were significantly increased in patients with COVID-19 compared with patients with sepsis. No significant differences have been noted in platelet counts, PT or APTT among the four stages of COVID-19, although platelet counts tend to be reduced in severe or critical illness [46]. Therefore, the above scoring system may not be useful for diagnosing thrombosis in patients with COVID-19, suggesting that coagulation factor abnormalities may not be significant in COVID-19.

5.2. Platelet Activation

Platelet activation can be evaluated to detect substances such as P selectin [53] or phosphatidylserine [54] on the platelet surface via flow cytometry. However, this method is not routine laboratory work. Platelet–leukocyte aggregates are often detected to show platelet activation [55], but this method is not quantitative (Table 3). Microparticles with tissue factor (TF) from platelets or vessels have been reported to be increased in patients with thrombosis [56], but this method is still being researched. Although, the β-thromboglobulin (β-TG), platelet factor 4 (PF4), and P-selectin are considered biomarkers of platelet activation, their diagnostic specificity for thrombosis due to platelet activation is not high, and their clinical laboratory use is inconvenient [57].
Soluble platelet membrane glycoprotein VI (sGPVI) and soluble C-type lectin-like receptor 2 (sCLEC-2) have been reported as new biomarkers for platelet activation [16,17,57]. Both sGPVI and sCLEC-2 were significantly elevated in patients with TMA and DIC [17,51]. Elevated sCLEC-2 levels were also reported in patients with ACS [18], ACI [58] and COVID-19 [46]. Specifically, the sCLEC-2/platelet ratio is useful for evaluating the severity of COVID-19. Furthermore, the plasma sCLEC-2 levels in patients with the mild stage of COVID-19 were similar to those in patients with other pneumonias, suggesting that the activation of platelets may occur in the early stage of COVID-19 without symptoms of microangiopathy [36]. Activated platelets in patients with COVID-19 may release large amounts of sCLEC-2 into the blood before causing severe microangiopathy. Although many reports have demonstrated decreased ADAMTS13 activity and increased von Willebrand factor (VWF) in patients with COVID-19 [59,60], ADAMTS-13 activity was not less than 10% in COVID-19 and the clinical usefulness of a mild decrease in ADAMTS-13 is not clear. Anti-PF 4 antibodies have often been reported in COVID-19 patients associated with thrombosis [61,62], suggesting that one of the thrombotic mechanisms in patients with COVID-19 is heparin-induced thrombocytopenia (HIT).
Table
Table 2. Routine biomarkers for coagulopathy in COVID-19 infections and sepsis.
Table 2. Routine biomarkers for coagulopathy in COVID-19 infections and sepsis.
COVID-19 Infection [14,15,52,54,55]Sepsis Due to Bacterial Infection [37,38,57,59]
Cutoff ValueSensitivitySpecificity Cutoff ValueSensitivitySpecificity
D-dimer1.0–3.0 μg/mLhighlow5–10 μg/mLmoderately highmoderately high
Platelet counts16.0 × 1010/Llowlow12.0 × 1010/Lmoderately highmoderately high
PT-INR1.20lowlow1.20moderately highmoderately high
Fibrinogenincreased--1.5 g/Lslightly highhigh
Antithrombin---70%moderately highmoderately high
WBCdecreased (at first) markedly increased
Hemoglobindecreased (at severe or critical illness)no change
PT-INR, prothrombin time-internationalized ratio; WBC, white blood cells; COVID-19, coronavirus disease 2019.
Table
Table 3. Examinations for platelet activation.
Table 3. Examinations for platelet activation.
MethodsQuantitativeMultiple AssayEasy AssaySpecificity
Activated substance on platelet flow cytometryNANAadequatespecific
Microparticles from plateletflow cytometry,
immunoassay		NANAadequatesemispecific
Platelet–leukocyte aggregatesflow cytometry,
microscopy		NANAadequatespecific
β-TG, platelet factor 4 (PF4)ELISAPAPANAspecific
P-secretinELISAadequateadequateadequatesemispecific
GP-VI, ELISAadequateadequateadequatespecific
sCLEC-2CLEIAadequateadequateSAspecific
β-TG, β-thromboglobulin; PF4, platelet factor 4; NA, not adequate; PA, partially adequate; SA, strongly adequate; sGPVI, soluble platelet membrane glycoprotein VI; sCLEC-2, soluble C-type lectin-like receptor 2; ELISA, enzyme-linked immunosorbent assay, CLEIA, chemiluminescent enzyme immunoassay.

5.3. Hypofibrinolysis and Vascular Endothelial Cell Injury Markers

Increased fibrinogen [63] and plasminogen activator inhibitor-1 (PAI-I) levels [64], slightly increased D-dimer levels [65], and viscoelastic whole blood coagulation testing with and without tissue plasminogen activator [66,67] suggested a hypercoagulable and hypofibrinolytic state in patients with COVID-19. Most studies that reported hypofibrinolysis in patients with COVID-19 [66,67,68] used thromboelastography (TEG), and conducting statistical analyses for hypofibrinolysis proved difficult. Therefore, the hypofibrinolytic state in COVID-19 has not yet been sufficiently evaluated. Although it has been emphasized that D-dimer levels are increased in COVID-19 patients with severe or critical illness [36], the increase in D-dimer values in patients with COVID-19 has been shown to be significantly lower than that in other pneumonia patients [69]. Organ failure is worse in advanced COVID-19 patients, so vascular endothelial cell injury markers such as soluble thrombomodulin (sTM), VWF and PAI-I are high, while AT levels are low, suggesting that hypofibrinolysis may be related to organ failure and vascular endothelial cell injury.

5.4. Inflammatory Marker

Increased values for the white blood cell count, C-reactive protein (CRP) level [8], procalcitonin level [70], presepsin level [71], C5b-9 and C5a levels [44], and levels of inflammatory cytokines, such as tumor necrosis factor α, interleukin-1, interleukin-2, interleukin-6, interleukin-10 and interferon γ, were reported in patients with severe COVID-19; elevation in these inflammatory factors can lead to cytokine storm [72]. As procalcitonin is a biomarker for bacterial infection, presepsin may be more useful for diagnosing COVID-19 than procalcitonin [73]. These inflammatory mediators can further cause hypercoagulability, platelet activation, hypofibrinolysis, and vascular endothelial cell injuries by activating leukocytes, vascular endothelial cells and platelets.

6. Mechanisms for Thrombosis in COVID-19 and Sepsis

Several mechanisms for thrombosis underlying the worsening of the condition of COVID-19 patients, such as old age, long time-bed rest and comorbidities [23,28], inflammation and cytokine storms [12], vascular endothelial injuries [74], primary pulmonary thrombosis [75], hypoventilation, a hypercoagulable state (including activation of the TF pathway) [74], neutrophil extracellular traps (NETs) [76], hypofibrinolysis [66] and platelet activation [60], have been proposed. The mechanism underlying thrombosis in COVID-19 (Figure 3) and in bacterial infection (Figure 4) is shown.

6.1. Platelet Activation

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) binds to the CD-147 receptor of platelets [77]. Early and intense platelet activation, which was reproduced in vitro by stimulating platelets with SARS-CoV-2 depending on the CD147 receptor, has been reported [53]. Platelet activation and platelet–monocyte aggregate formation trigger TF expression in patients with severe COVID-19 [78]. SARS-CoV-2-induced platelet activation may participate in thrombus formation and inflammatory responses in COVID-19 patients. The early accumulation of extracellular vesicles with the soluble P-selectin and high mobility group box 1 (HMGB-1) protein which platelets release, was shown to predict worse clinical outcomes [53]. The plasma sCLEC-2 levels in patients with COVID-19 were significantly higher than those in patients with other infections and reflected the progression of the severity of COVID-19 although these levels were significantly higher in patients with sepsis due to bacterial infection [46] (Figure 4).
Thrombocytopenia is often observed in COVID-19 patients with severe disease as well as in septic patients with DIC [79]. The sCLEC-2/platelet ratio was significantly higher in COVID-19 patients with severe and critical illness than in those with mild illness, suggesting that one of the causes of thrombocytopenia might be consumption due to microthrombi formation, suggesting that COVID-19 has microangiopathy as well as DIC or TMA. Low-dose aspirin was reported to be useful for managing COVID-19 [80].

6.2. Hypercoagulable State

Marked activation of leukocytes and the overexpression of TF are considered some of the most important causes of thrombosis or DIC due to bacterial infection [14,79]. Markedly increased values of white blood cell count, plasma TF, and TF messenger RNA levels in white blood cells have been reported in patients with sepsis [81]. Increased levels of inflammatory cytokines, fibrin-related products (e.g., D-dimer), vascular endothelial cell injury markers (e.g., thrombomodulin [TM]), and PAI-I and decreased antithrombin, thrombocytopenia, and a prolonged PT were also reported in septic patients [14,38,82]. Such cases of sepsis are frequently associated with DIC [38]. Severe septic patients with elevated sCLEC-2 levels may also have microangiopathy [46]. There are some differences in the mechanism underlying thrombocytopenia between DIC and TMA [79], although thrombocytopenia in both diseases is caused by platelet consumption. Regarding COVID -19 (Figure 3), leukocyte counts are generally decreased early in COVID-19 [8], suggesting that activated platelets and injured vascular endothelial cells may play an important role in the onset of thrombosis through CD-147 [53]. However, CWA-APTT and CWA-sTF/FIXa showed hypercoagulability in patients with COVID-19 [41] suggesting that thrombin burst (Figure 2) [83] which is enhanced by activated platelets, causes hypercoagulability in this state.

6.3. Hypofibrinolysis

Although both severe COVID-19 and bacterial infections may have similar microangiopathy, complications with VTE are frequent in patients with COVID-19 but are not frequent in septic patients. DIC is caused by hypercoagulation and hyperfibrinolysis [38], most microthrombi in the microvasculature may dissolve promptly in DIC, whereas microthrombi in COVID-19 may develop into venous thrombosis. Vascular injuries are observed in COVID-19 [74], suggesting that elevated PAI-I may inhibit fibrinolysis [84] (Table 4 and Table 5). In addition, the sCLEC-2/D-dimer ratio in patients with COVID-19 was significantly higher than that in patients with other infections [69], suggesting that hypercoagulable and hypofibrinolysis states are more predominant in patients with COVID-19 than in other pneumonia patients. Markedly increased TF and D-dimer levels are observed in cases of bacterial infection [38,81], suggesting that hypercoagulable and hyperfibrinolytic states exist in severe bacterial infections. Regarding COVID-19 infection, the sCLEC-2/D-dimer ratio in cases with critical illness was significantly lower than that in cases with mild illness, suggesting that most patients with early-stage COVID-19 infection show only platelet activation with hypofibrinolysis, and that severe COVID-19 causes even further hypercoagulability [69] through a thrombin burst induced by platelet activation (Figure 4).

7. Treatment and Prophylaxis for Thrombosis

Although antithrombotic agents such as heparin reduce the risk of thromboembolism in severely ill patients, there are a few recommendations for patients with COVID-19 in the ISTH guidelines on antithrombotic treatment [85]. Among non-critically ill patients hospitalized for COVID-19, there is a strong recommendation for the use of prophylactic doses of low molecular weight heparin (LMWH) or unfractionated heparin (UFH) and for select patients in this group; the use of therapeutic doses LMWH/UFH is preferred over prophylactic doses, but without the addition of an antiplatelet agent. There are weak recommendations for adding an antiplatelet agent to prophylactic LMWH/UFH in select critically ill patients and prophylactic rivaroxaban for select patients after discharge. A recent review of RCTs [86] in critically ill patients demonstrated that a therapeutic dose of anticoagulation does not improve outcomes and results in more bleeding than a prophylactic dose of anticoagulant in these patients. Trials in noncritically ill hospitalized patients showed that anticoagulation at a therapeutic dose with a heparin formulation might improve clinical outcomes. Anticoagulation with a direct oral anticoagulant may improve outcomes of posthospital discharge; the results of a large RCT that is currently in progress are awaited [87]. There is not sufficient evidence that therapeutic anticoagulant can be recommended in critically ill patients at the present time.

8. Conclusions

A hypercoagulable state, platelet activation (observed as the marked elevation of sCLEC-2), and hypofibrinolysis due to vascular injuries are observed in patients with COVID-19, suggesting that SARS-CoV-2 may cause thrombogenicity via a mechanism different from that involved in bacterial infection.

Author Contributions

Conceptualization, H.W.; methodology, K.S.-I.; validation, K.S.; formal analysis, M.S.; investigation, T.I.; writing—original draft preparation, H.W.; writing—review and editing, M.S.; visualization, T.I.; supervision, H.S.; project administration, K.S.; funding acquisition, H.W. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Japanese Ministry of Health, Labor and Welfare (grant number 21FC1008). The APC was funded by Mie University.

Institutional Review Board Statement

The study protocol (2020-S25) was approved by the Human Ethics Review committees of Mie Prefectural General Medical Center. This study was faithfully carried out in accordance with the principles of the Declaration of Helsinki.

Informed Consent Statement

We did not directly use patient data that required informed consent.

Data Availability Statement

Yes, available in References.

Conflicts of Interest

The measurements of sCLEC-2 and D-dimer levels were partially supported by LSI Medience. The authors declare no other conflict of interest in association with the present study.

References

  1. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [Google Scholar] [CrossRef] [PubMed]
  2. Jiang, F.; Deng, L.; Zhang, L.; Cai, Y.; Cheung, C.W.; Xia, Z.J. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). Gen. Intern. Med. 2020, 35, 1545–1549. [Google Scholar] [CrossRef] [PubMed]
  3. Gavriatopoulou, M.; Ntanasis-Stathopoulos, I.; Korompoki, E.; Fotiou, D.; Migkou, M.; Tzanninis, I.-G.; Psaltopoulou, T.; Kastritis, E.; Terpos, E.; Dimopoulos, M.A. Emerging treatment strategies for COVID-19 infection. Clin. Exp. Med. 2020, 21, 167–179. [Google Scholar] [CrossRef] [PubMed]
  4. Machhi, J.; Herskovitz, J.; Senan, A.M.; Dutta, D.; Nath, B.; Oleynikov, M.D.; Blomberg, W.R.; Meigs, D.D.; Hasan, M.; Patel, M.; et al. The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. J. Neuroimmune Pharmacol. 2020, 15, 359–386. [Google Scholar] [CrossRef]
  5. Hertanto, D.M.; Wiratama, B.S.; Sutanto, H.; Wungu, C.D.K. Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. J. Inflamm. Res. 2021, 14, 3419–3428. [Google Scholar] [CrossRef]
  6. Berlin, D.A.; Gulick, R.M.; Martinez, F.J. Severe COVID-19. N. Engl. J. Med. 2020, 383, 2451–2460. [Google Scholar] [CrossRef]
  7. Gandhi, R.T.; Lynch, J.B.; Del Rio, C. Mild or Moderate COVID-19. N. Engl. J. Med. 2020, 383, 1757–1766. [Google Scholar] [CrossRef]
  8. Yamamoto, A.; Wada, H.; Ichikawa, Y.; Mizuno, H.; Tomida, M.; Masuda, J.; Makino, K.; Kodama, S.; Yoshida, M.; Fukui, S.; et al. Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection. J. Clin. Med. 2021, 10, 3775. [Google Scholar] [CrossRef]
  9. Karim, S.S.A.; Karim, Q.A. Omicron SARS-CoV-2 variant: A new chapter in the COVID-19 pandemic. Lancet 2021, 398, 2126–2128. [Google Scholar] [CrossRef]
  10. Jiménez, D.; García-Sanchez, A.; Rali, P.; Muriel, A.; Bikdeli, B.; Ruiz-Artacho, P.; Le Mao, R.; Rodríguez, C.; Hunt, B.J.; Monreal, M. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest 2021, 159, 1182–1196. [Google Scholar] [CrossRef]
  11. Nannoni, S.; de Groot, R.; Bell, S.; Markus, H.S. Stroke in COVID-19: A systematic review and meta-analysis. Int. J. Stroke 2021, 16, 137–149. [Google Scholar] [CrossRef] [PubMed]
  12. Zhao, Y.H.; Zhao, L.; Yang, X.C.; Wang, P. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): A systematic review and meta-analysis. Rev. Cardiovasc. Med. 2021, 22, 159–165. [Google Scholar] [CrossRef] [PubMed]
  13. Chan, N.C.; Weitz, J.I. COVID-19 coagulopathy, thrombosis, and bleeding. Blood 2020, 136, 381–383. [Google Scholar] [CrossRef] [PubMed]
  14. Wada, H.; Thachil, J.; Di Nisio, M.; Mathew, P.; Kurosawa, S.; Gando, S.; Kim, H.K.; Nielsen, J.D.; Dempfle, C.E.; Levi, M.; et al. The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis: Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J. Thromb. Haemost. 2013, 11, 761–767. [Google Scholar] [CrossRef]
  15. Wada, H.; Matsumoto, T.; Yamashita, Y. Natural History of Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome. Semin. Thromb. Hemost. 2014, 40, 866–873. [Google Scholar]
  16. Suzuki-Inoue, K.; Fuller, G.L.; Garcia, A.; Eble, J.A.; Pohlmann, S.; Inoue, O.; Gartner, T.K.; Hughan, S.C.; Pearce, A.C.; Laing, G.D.; et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor sCLEC-2. Blood 2006, 107, 542–549. [Google Scholar] [CrossRef]
  17. Yamashita, Y.; Suzuki, K.; Mastumoto, T.; Ikejiri, M.; Ohishi, K.; Katayama, N.; Suzuki-Inoue, K.; Wada, H. Elevated plasma levels of soluble C-type lectin-like receptor 2 (sCLEC-2) in patients with thrombotic microangiopathy. Thromb. Res. 2019, 178, 54–58. [Google Scholar] [CrossRef]
  18. Inoue, O.; Osada, M.; Nakamura, J.; Kazama, F.; Shirai, T.; Tsukiji, N.; Sasaki, T.; Yokomichi, H.; Dohi, T.; Kaneko, M.; et al. Soluble CLEC-2 is generated independently of ADAM10 and is increased in plasma in acute coronary syndrome: Comparison with soluble GPVI. Int. J. Hematol. 2019, 110, 285–294. [Google Scholar] [CrossRef]
  19. Cheng, N.M.; Chan, Y.C.; Cheng, S.W. COVID-19 related thrombosis: A mini-review. Phlebology 2022, 10, 2683555211052170. [Google Scholar] [CrossRef]
  20. Suh, Y.J.; Hong, H.; Ohana, M.; Bompard, F.; Revel, M.P.; Valle, C.; Gervaise, A.; Poissy, J.; Susen, S.; Hékimian, G.; et al. Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis. Radiology 2021, 298, E70–E80. [Google Scholar] [CrossRef]
  21. Malas, M.B.; Naazie, I.N.; Elsayed, N.; Mathlouthi, A.; Marmor, R.; Clary, B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. eClin. Med. 2020, 29, 100639. [Google Scholar] [CrossRef] [PubMed]
  22. Peiris, S.; Ordunez, P.; DiPette, D.; Padwal, R.; Ambrosi, P.; Toledo, J.; Stanford, V.; Lisboa, T.; Aldighieri, S.; Reveiz, L. Cardiac Manifestations in Patients with COVID-19: A Scoping Review. Glob. Heart 2022, 17, 2. [Google Scholar] [CrossRef] [PubMed]
  23. Roshdy, A.; Zaher, S.; Fayed, H.; Coghlan, J.G. COVID-19 and the Heart: A Systematic Review of Cardiac Autopsies. Front. Cardiovasc. Med. 2021, 7, 626975. [Google Scholar] [CrossRef] [PubMed]
  24. Thakker, R.A.; Elbadawi, A.; Chatila, K.F.; Goel, S.S.; Reynoso, D.; Berbarie, R.F.; Gilani, S.; Rangasetty, U.; Khalife, W. Comparison of Coronary Artery Involvement and Mortality in STEMI Patients with and without SARS-CoV-2 during the COVID-19 Pandemic: A Systematic Review and Meta-Analysis. Curr. Probl. Cardiol. 2022, 47, 101032. [Google Scholar] [CrossRef] [PubMed]
  25. Choi, Y.; Lee, M.K. Neuroimaging findings of brain MRI and CT in patients with COVID-19: A systematic review and meta-analysis. Eur. J. Radiol. 2020, 133, 109393. [Google Scholar] [CrossRef] [PubMed]
  26. Kim, P.H.; Kim, M.; Suh, C.H.; Chung, S.R.; Park, J.E.; Kim, S.C.; Choi, Y.J.; Lee, J.H.; Kim, H.S.; Baek, J.H.; et al. Neuroimaging Findings in Patients with COVID-19: A Systematic Review and Meta-Analysis. Korean J. Radiol. 2021, 22, 1875–1885. [Google Scholar] [CrossRef]
  27. Horiuchi, H.; Morishita, E.; Urano, T.; Yokoyama, K. Questionnaire-survey Joint Team on The COVID-19-related thrombosis: COVID-19-Related Thrombosis in Japan: Final Report of a Questionnaire-Based Survey in 2020. J. Atheroscler. Thromb. 2021, 28, 400–406. [Google Scholar] [CrossRef]
  28. Qureshi, A.I.; Baskett, W.I.; Huang, W.; Shyu, D.; Myers, D.; Raju, M.; Lobanova, I.; Suri, M.F.K.; Naqvi, S.H.; French, B.R.; et al. Acute ischemic stroke and COVID-19: An analysis of 27 676 patients. Stroke 2021, 52, 905–912. [Google Scholar] [CrossRef]
  29. Xiao, D.; Tang, F.; Chen, L.; Gao, H.; Li, X. Cumulative Evidence for the Association of Thrombosis and the Prognosis of COVID-19: Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 2022, 8, 819318. [Google Scholar] [CrossRef]
  30. Pepera, G.; Tribali, M.S.; Batalik, L.; Petrov, I.; Papathanasiou, J. Epidemiology, risk factors and prognosis of cardiovascular disease in the Coronavirus Disease 2019 (COVID-19) pandemicera: A systematic review. Rev. Cardiovasc. Med. 2022, 23, 28. [Google Scholar] [CrossRef]
  31. Giannis, D.; Allen, S.L.; Tsang, J.; Flint, S.; Pinhasov, T.; Williams, S.; Tan, G.; Thakur, R.; Leung, C.; Snyder, M.; et al. Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: The CORE-19 registry. Blood 2021, 137, 2838–2847. [Google Scholar] [CrossRef] [PubMed]
  32. Iba, T.; Levy, J.H.; Levi, M.; Thachil, J. Coagulopathy in COVID-19. J. Thromb. Haemost. 2020, 18, 2103–2109. [Google Scholar] [CrossRef] [PubMed]
  33. Zhou, X.; Cheng, Z.; Luo, L.; Zhu, Y.; Lin, W.; Ming, Z.; Chen, W.; Hu, Y. Incidence and impact of disseminated intravascular coagulation in COVID-19 a systematic review and meta-analysis. Thromb. Res. 2021, 201, 23–29. [Google Scholar] [CrossRef] [PubMed]
  34. Larsen, J.B.; Aggerbeck, M.A.; Granfeldt, A.; Schmidt, M.; Hvas, A.M.; Adelborg, K. Res Pract: Disseminated intravascular coagulation diagnosis: Positive predictive value of the ISTH score in a Danish population. Thromb. Haemost. 2021, 5, e12636. [Google Scholar]
  35. Gando, S.; Shiraishi, A.; Yamakawa, K.; Ogura, H.; Saitoh, D.; Fujishima, S.; Mayumi, T.; Kushimoto, S.; Abe, T.; Shiino, Y.; et al. Role of disseminated intravascular coagulation in severe sepsis. Japanese Association for Acute Medicine (JAAM) Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis and Trauma (FORECAST) Study Group. Thromb. Res. 2019, 178, 182–188. [Google Scholar] [CrossRef] [PubMed]
  36. Yamakawa, K.; Aihara, M.; Ogura, H.; Yuhara, H.; Hamasaki, T.; Shimazu, T. Recombinant human soluble thrombomodulin in severe sepsis: Systematic review and meta-analysis. J. Thromb. Haemost. 2015, 13, 508–519. [Google Scholar] [CrossRef]
  37. Tagami, T. Antithrombin concentrate use in sepsis-associated disseminated intravascular coagulation: Re-evaluation of a ‘pendulum effect’ drug using a nationwide database. J. Thromb. Haemost. 2018, 16, 458–461. [Google Scholar] [CrossRef]
  38. Wada, H.; Matsumoto, T.; Yamashita, Y. Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J. Intensive Care 2014, 2, 15. [Google Scholar] [CrossRef]
  39. Wada, H.; Matsumoto, T.; Ohishi, K.; Shiraki, K.; Shimaoka, M. Update on the Clot Waveform Analysis. Clin. Appl. Thromb. Hemost. 2020, 26, 1076029620912027. [Google Scholar] [CrossRef]
  40. Suzuki, K.; Wada, H.; Imai, H.; Iba, T.; Thachil, J.; Toh, C.H. Subcommittee on Disseminated Intravascular Coagulation. A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt-DIC diagnostic criteria: Communication from the SSC of the ISTH. J. Thromb. Haemost. 2018, 16, 1442–1444. [Google Scholar] [CrossRef]
  41. Suzuki1, K.; Wada, H.; Ikejiri, K.; Ito, A.; Matsumoto, T.; Tone, S.; Hasegawa, M.; Shimaoka, M.; Iba, T.; Imai, H. Prolongation of Peak Time but an Elevated Peak Height of a Clot Wave Form Analysis in Severe Coronavirus Disease 2019. Med. Res. Arch. 2023, 11. Available online: https://esmed.org/MRA/index.php/mra/article/view/3549 (accessed on 25 April 2023).
  42. Tiwari, N.R.; Phatak, S.; Sharma, V.R.; Agarwal, S.K. COVID-19 and thrombotic microangiopathies. Thromb. Res. 2021, 202, 191–198. [Google Scholar] [CrossRef]
  43. Diorio, C.; McNerney, K.O.; Lambert, M.; Paessler, M.; Anderson, E.M.; Henrickson, S.E.; Chase, J.; Liebling, E.J.; Burudpakdee, C.; Lee, J.H.; et al. Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Adv. 2020, 4, 6051–6063. [Google Scholar] [CrossRef] [PubMed]
  44. Detsika, M.G.; Diamanti, E.; Ampelakiotou, K.; Jahaj, E.; Tsipilis, S.; Athanasiou, N.; Dimopoulou, I.; Orfanos, S.E.; Tsirogianni, A.; Kotanidou, A. C3a and C5b-9 Differentially Predict COVID-19 Progression and Outcome. Life 2022, 12, 1335. [Google Scholar] [CrossRef] [PubMed]
  45. Mancini, I.; Baronciani, L.; Artoni, A.; Colpani, P.; Biganzoli, M.; Cozzi, G.; Novembrino, C.; Anzoletti, M.B.; De Zan, V.; Pagliari, M.T.; et al. The ADAMTS13-von Willebrand factor axis in COVID-19 patients. J. Thromb. Haemost. 2021, 19, 513–521. [Google Scholar] [CrossRef] [PubMed]
  46. Wada, H.; Ichikawa, Y.; Ezaki, M.; Yamamoto, A.; Tomida, M.; Yoshida, M.; Fukui, S.; Moritani, I.; Shiraki, K.; Shimaoka, M.; et al. Elevated Plasma Soluble C-Type Lectin-like Receptor 2 Is Associated with the Worsening of Coronavirus Disease 2019. J. Clin. Med. 2022, 11, 985. [Google Scholar] [CrossRef]
  47. Wada, H.; Shiraki, K.; Matsumoto, T.; Shimpo, H.; Yamashita, Y.; Shimaoka, M. The evaluation of a scoring system for diagnosing atypical hemolytic uremic syndrome—A review analysis for Japanese aHUS. Thrmbosis Update 2020, 1, 100012. [Google Scholar] [CrossRef]
  48. Matsunaga, N.; Hayakawa, K.; Terada, M.; Ohtsu, H.; Asai, Y.; Tsuzuki, S.; Suzuki, S.; Toyoda, A.; Suzuki, K.; Endo, M.; et al. Clinical epidemiology of hospitalized patients with COVID-19 in Japan: Report of the COVID-19 Registry Japan. Clin. Infect. Dis. 2021, 73, e3677–e3689. [Google Scholar] [CrossRef]
  49. Yang, X.; Yang, Q.; Wang, Y.; Wu, Y.; Xu, J.; Yu, Y.; Shang, Y. Thrombocytopenia and its association with mortality in patients with COVID-19. J. Thromb. Haemost. 2020, 18, 1469–1472. [Google Scholar] [CrossRef]
  50. Wada, H.; Takahashi, H.; Uchiyama, T.; Eguchi, Y.; Okamoto, K.; Kawasugi, K.; Madoiwa, S.; Asakura, H. DIC subcommittee of the Japanese Society on Thrombosis and Hemostasis: The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb. J. 2017, 15, 17. [Google Scholar] [CrossRef]
  51. Iba, T.; Levy, J.H.; Raj, A.; Warkentin, T.E. Advance in the Management of Sepsis–Induced Coagulopathy and Disseminated Intravascular Coagulation. J. Clin. Med. 2019, 8, 728. [Google Scholar] [CrossRef] [PubMed]
  52. Wada, H.; Yamamoto, A.; Tomida, M.; Ichikawa, Y.; Ezaki, M.; Masuda, J.; Yoshida, M.; Fukui, S.; Moritani, I.; Inoue, H.; et al. Proposal of Quick Diagnostic Criteria for Disseminated Intravascular Coagulation. J. Clin. Med. 2022, 11, 1028. [Google Scholar] [CrossRef] [PubMed]
  53. Maugeri, N.; De Lorenzo, R.; Clementi, N.; Antonia; Diotti, R.; Criscuolo, E.; Godino, C.; Tresoldi, C.; Bonini, C.; Clementi, M.; et al. Unconventional CD147-dependent platelet activation elicited by SARS-CoV-2 in COVID-19. J. Thromb. Haemost. 2022, 20, 434–448. [Google Scholar] [CrossRef] [PubMed]
  54. Lee, C.S.M.; Selvadurai, M.V.; Pasalic, L.; Yeung, J.; Konda, M.; Kershaw, G.W.; Favaloro, E.J.; Chen, V.M. Measurement of procoagulant platelets provides mechanistic insight and diagnostic potential in heparin-induced thrombocytopenia. J. Thromb. Haemost. 2022, 20, 975–988. [Google Scholar] [CrossRef]
  55. Jennings, L.K. Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb. Haemost. 2009, 102, 248–257. [Google Scholar] [CrossRef]
  56. Sánchez-López, V.; Gao, L.; Ferrer-Galván, M.; Arellano-Orden, E.; Elías-Hernández, T.; Jara-Palomares, L.; Asensio-Cruz, M.I.; Castro-Pérez, M.J.; Rodríguez-Martorell, F.J.; Lobo-Beristain, J.L.; et al. Differential biomarker profiles between unprovoked venous thromboembolism and cancer. Ann. Med. 2020, 52, 310–320. [Google Scholar] [CrossRef]
  57. Yamashita, Y.; Naitoh, K.; Wada, H.; Ikejiri, M.; Mastumoto, T.; Ohishi, K.; Hosaka, Y.; Nishikawa, M.; Katayama, N. Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. Thromb. Res 2014, 133, 440–444. [Google Scholar] [CrossRef]
  58. Nishigaki, A.; Ichikawa, Y.; Ezaki, E.; Yamamoto, A.; Suzuki, K.; Tachibana, K.; Kamon, T.; Horie, S.; Masuda, J.; Makino, K.; et al. Soluble C-type lectin-like receptor 2 elevation in patients with acute cerebral infarction. J. Clin. Med. 2021, 10, 3408. [Google Scholar] [CrossRef]
  59. Favaloro, E.J.; Henry, B.M.; Lippi, G. Increased VWF and Decreased ADAMTS-13 in COVID-19: Creating a Milieu for (Micro)Thrombosis. Semin. Thromb. Hemost. 2021, 47, 400–418. [Google Scholar] [CrossRef]
  60. Sweeney, J.M.; Barouqa, M.; Krause, G.J.; Gonzalez-Lugo, J.D.; Rahman, S.; Gil, M.R. Low ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 Patients. TH Open 2021, 5, e89–e103. [Google Scholar]
  61. Nazy, I.; Jevtic, S.D.; Moore, J.C.; Huynh, A.; Smith, J.W.; Kelton, J.G.; Arnold, D.M. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J. Thromb. Haemost. 2021, 19, 1342–1347. [Google Scholar] [CrossRef] [PubMed]
  62. Favaloro, E.J.; Henry, B.M.; Lippi, G. The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19. Int. J. Lab. Hematol. 2021, 43, 547–558. [Google Scholar] [CrossRef] [PubMed]
  63. Schrick, D.; Tőkés-Füzesi, M.; Réger, B.; Molnár, T. Metabolites: Plasma Fibrinogen Independently Predicts Hypofibrinolysis in Severe COVID-19. Metabolities 2021, 11, 826. [Google Scholar] [CrossRef]
  64. Nougier, C.; Benoit, R.; Simon, M.; Desmurs-Clavel, H.; Marcotte, G.; Argaud, L.; David, J.S.; Bonnet, A.; Negrier, C.; Dargaud, Y.J. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J. Thromb. Haemost. 2020, 18, 2215–2219. [Google Scholar] [CrossRef] [PubMed]
  65. Kruse, J.M.; Magomedov, A.; Kurreck, A.; Münch, F.H.; Koerner, R.; Kamhieh-Milz, J.; Kahl, A.; Gotthardt, I.; Piper, S.K.; Eckardt, K.U.; et al. Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. Crit. Care 2020, 24, 676. [Google Scholar] [CrossRef]
  66. Bachler, M.; Bösch, J.; Stürzel, D.P.; Hell, T.; Giebl, A.; Ströhle, M.; Klein, S.J.; Schäfer, V.; Lehner, G.F.; Joannidis, M.; et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br. J. Anaesth. 2021, 126, 590–598. [Google Scholar] [CrossRef]
  67. Bareille, M.; Hardy, M.; Douxfils, J.; Roullet, S.; Lasne, D.; Levy, J.H.; Stépanian, A.; Susen, S.; Frère, C.; Lecompte, T.; et al. Viscoelastometric Testing to Assess Hemostasis of COVID-19: A Systematic Review. J. Clin. Med. 2021, 10, 1740. [Google Scholar] [CrossRef]
  68. Pavoni., V.; Gianesello, L.; Pazzi, M.; Dattolo, P.; Prisco, D. Questions about COVID-19 associated coagulopathy: Possible answers from the viscoelastic tests. J. Clin. Monit. Comput. 2022, 36, 55–69. [Google Scholar] [CrossRef]
  69. Wada, H.; Shiraki, K.; Suzuki-Inoue, K. Comments to: Unconventional CD147-platelet activation elicited by SARS-CoV-2 in COVID-19: sCLEC-2 is new marker for platelet activation by COVID-19. J. Thromb. Haemost. 2022, 20, 2159–2160. [Google Scholar] [CrossRef]
  70. Zhao, Y.; Yin, L.; Patel, J.; Tang, L.; Huang, Y. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis. J. Med. Virol. 2021, 93, 4358–4369. [Google Scholar] [CrossRef]
  71. Guarino, M.; Perna, B.; Maritati, M.; Remelli, F.; Trevisan, C.; Spampinato, M.D.; Costanzini, A.; Volpato, S.; Contini, C.; De Giorgio, R. Presepsin levels and COVID-19 severity: A systematic review and meta-analysis. Clin. Exp. Med. 2022, 1–10. [Google Scholar] [CrossRef] [PubMed]
  72. Montazersaheb, S.; Hosseiniyan Khatibi, S.M.; Hejazi, M.S.; Tarhriz, V.; Farjami, A.; Ghasemian Sorbeni, F.; Farahzadi, R.; Ghasemnejad, T. COVID-19 infection: An overview on cytokine storm and related interventions. Virol. J. 2022, 19, 92. [Google Scholar] [CrossRef] [PubMed]
  73. Fukui, S.; Ikeda, K.; Kobayashi, M.; Nishida, K.; Yamada, K.; Horie, S.; Shimada, Y.; Miki, H.; Goto, H.; Hayashi, K.; et al. Predictive prognostic biomarkers in patients with COVID-19 infection. Mol. Med. Rep. 2023, 27, 15. [Google Scholar] [CrossRef] [PubMed]
  74. Connors, J.M.; Levy, J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020, 135, 2033–2040. [Google Scholar] [CrossRef]
  75. Gabrielli, M.; Lamendola, P.; Esperide, A.; Valletta, F.; Franceschi, F. COVID-19 and thrombotic complications: Pulmonary thrombosis rather than embolism? Thromb. Res. 2020, 193, 98. [Google Scholar] [CrossRef]
  76. Zuo, Y.; Yalavarthi, S.; Shi, H.; Gockman, K.; Zuo, M.; Madison, J.A.; Blair, C.; Weber, A.; Barnes, B.J.; Egeblad, M.; et al. Neutrophil extracellular traps (NETs) in COVID-19. JCI Insight 2020, 5, e138999. [Google Scholar]
  77. Zhang, S.; Liu, Y.; Wang, X.; Yang, L.; Li, H.; Wang, Y.; Liu, M.; Zhao, X.; Xie, Y.; Yang, Y.; et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. J. Hematol. Oncol. 2020, 13, 120. [Google Scholar] [CrossRef]
  78. Hottz, E.D.; Azevedo-Quintanilha, I.G.; Palhinha, L.; Teixeira, L.; Barreto, E.A.; Pão, C.R.R.; Righy, C.; Franco, S.; Souza, T.M.L.; Kurtz, P.; et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood 2020, 136, 1330–1341. [Google Scholar] [CrossRef]
  79. Wada, H.; Matsumoto, T.; Suzuki, K.; Imai, H.; Katayama, N.; Iba, T.; Matsumoto, M. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb. J. 2018, 16, 14. [Google Scholar] [CrossRef]
  80. Salah, H.M.; Mehta, J.L. Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19. Am. J. Cardiol. 2021, 142, 158–159. [Google Scholar] [CrossRef]
  81. Sase, T.; Wada, H.; Kamikura, Y.; Kaneko, T.; Abe, Y.; Nishioka, J.; Nobori, T.; Shiku, H. Tissue factor messenger RNA levels in leukocytes compared with tissue factor antigens in plasma from patients in hypercoagulable state caused by various diseases. Thromb. Haemost. 2004, 92, 132–139. [Google Scholar] [CrossRef] [PubMed]
  82. Wada, H.; Minamikawa, K.; Wakita, Y.; Nakase, T.; Kaneko, T.; Ohiwa, M.; Tamaki, S.; Deguchi, K.; Shirakawa, S.; Hayashi, T.; et al. Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am. J. Hematol. 1993, 44, 85–88. [Google Scholar] [CrossRef] [PubMed]
  83. Wada, H.; Ichikawa, Y.; Ezaki, E.; Matsumoto, T.; Yamashita, Y.; Shiraki, K.; Shimaoka, M.; Shimpo, H. The reevaluation of thrombin time using a clot waveform analysis. J. Clin. Med. 2021, 10, 4840. [Google Scholar] [CrossRef] [PubMed]
  84. Han, M.; Pandey, D. ZMPSTE24 Regulates SARS-CoV-2 Spike Protein-enhanced Expression of Endothelial PAI-1. Am. J. Respir. Cell Mol. Biol. 2021, 65, 300–308. [Google Scholar] [CrossRef] [PubMed]
  85. Connors, J.M.; Falanga, A.; Iba, T.; Kaatz, S.; Levy, J.H.; Middeldorp, S.; Minichiello, T.; Ramacciotti, E.; Samama, C.M.; Thachil, J. International Society on Thrombosis and Haemostasis. ISTH guidelines for antithrombotic treatment in COVID-19. J. Thromb. Haemost. 2022, 20, 2214–2225. [Google Scholar]
  86. Rizk, J.G.; Gupta, A.; Lazo JGJr Sardar, P.; Henry, B.M.; Lavie, C.J.; Effron, M.B. To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Semin. Thromb. Hemost. 2023, 49, 62–72. [Google Scholar] [CrossRef]
  87. Berger, J.S.; Van Tassell, B.W.; Middeldorp, S.; Piazza, G.; Weitz, J.I.; Cushman, M.; Lip, G.Y.H.; Goldhaber, S.Z.; Bikdeli, B. Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. J. Thromb. Haemost. 2021, 19, 3080–3089. [Google Scholar]
Ijms 24 07975 g001 550
Figure 1. Variety of severity and complications of thrombosis in COVID-19.
Figure 1. Variety of severity and complications of thrombosis in COVID-19.
Ijms 24 07975 g001
Ijms 24 07975 g002 550
Figure 2. Difference in the CWA-APTT between COVID-19 coagulopathy with thrombin burst (a) and overt-DIC (b). CWA, clot waveform analysis; APTT, activated partial thromboplastin time; HV, healthy volunteer; COVID-19, coronavirus disease 2019; DIC, disseminated intravascular coagulation; navy line, fibrin formation curve; pink line, 1st derivative curve (velocity); light blue, 2nd derivative curve (acceleration); solid line, patient; dotted line, HV. A significant reduction in the peak height suggests bleeding, and a significant increase in the peak height suggest hypercoagulability and thrombotic risk. FX, activated FX; PLs, phospholipids; FVIIIa, activated FVIII, FVa, activated FV; FIXa, activated FIX; FXIa, activated FXI. A schematic illustration of thrombin burst in hypercoagulability with COVID-19.
Figure 2. Difference in the CWA-APTT between COVID-19 coagulopathy with thrombin burst (a) and overt-DIC (b). CWA, clot waveform analysis; APTT, activated partial thromboplastin time; HV, healthy volunteer; COVID-19, coronavirus disease 2019; DIC, disseminated intravascular coagulation; navy line, fibrin formation curve; pink line, 1st derivative curve (velocity); light blue, 2nd derivative curve (acceleration); solid line, patient; dotted line, HV. A significant reduction in the peak height suggests bleeding, and a significant increase in the peak height suggest hypercoagulability and thrombotic risk. FX, activated FX; PLs, phospholipids; FVIIIa, activated FVIII, FVa, activated FV; FIXa, activated FIX; FXIa, activated FXI. A schematic illustration of thrombin burst in hypercoagulability with COVID-19.
Ijms 24 07975 g002
Ijms 24 07975 g003 550
Figure 3. The mechanism underlying thrombosis in COVID-19. MΦ, macrophage; PMN, polymorphonuclear cell; NETS, neutrophil extracellular traps; ECs, endothelial cells; IFN, interferon; LPS, lipopolysaccharide; TF, tissue factor; IL, interleukin; TNF, tumor necrosis factor; TM, thrombomodulin; PAI-I, plasminogen activator inhibitor-1; AT-III, antithrombin; MOF, multiple organ failure; VTE, venous thromboembolism; DIC, disseminated intravascular coagulation; a★, activated platelet; PLT, platelet; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome related coronavirus-2; sCLEC-2, soluble C-type lectin-like receptor 2; TMA, thrombotic microangiopathy; VTE, venous thromboembolism; ATE, arterial thromboembolism.
Figure 3. The mechanism underlying thrombosis in COVID-19. MΦ, macrophage; PMN, polymorphonuclear cell; NETS, neutrophil extracellular traps; ECs, endothelial cells; IFN, interferon; LPS, lipopolysaccharide; TF, tissue factor; IL, interleukin; TNF, tumor necrosis factor; TM, thrombomodulin; PAI-I, plasminogen activator inhibitor-1; AT-III, antithrombin; MOF, multiple organ failure; VTE, venous thromboembolism; DIC, disseminated intravascular coagulation; a★, activated platelet; PLT, platelet; COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome related coronavirus-2; sCLEC-2, soluble C-type lectin-like receptor 2; TMA, thrombotic microangiopathy; VTE, venous thromboembolism; ATE, arterial thromboembolism.
Ijms 24 07975 g003
Ijms 24 07975 g004 550
Figure 4. The mechanism underlying thrombosis in bacterial infection. MΦ, macrophage; PMN, polymorphonuclear cell; NETS, neutrophil extracellular traps; ECs, endothelial cells; IFN, interferon; LPS, lipopolysaccharide; TF, tissue factor; IL, interleukin; TNF, tumor necrosis factor; TM, thrombomodulin; PAI-I, plasminogen activator inhibitor-1; AT-III, antithrombin; MOF, multiple organ failure; VTE, venous thromboembolism; DIC, disseminated intravascular coagulation.
Figure 4. The mechanism underlying thrombosis in bacterial infection. MΦ, macrophage; PMN, polymorphonuclear cell; NETS, neutrophil extracellular traps; ECs, endothelial cells; IFN, interferon; LPS, lipopolysaccharide; TF, tissue factor; IL, interleukin; TNF, tumor necrosis factor; TM, thrombomodulin; PAI-I, plasminogen activator inhibitor-1; AT-III, antithrombin; MOF, multiple organ failure; VTE, venous thromboembolism; DIC, disseminated intravascular coagulation.
Ijms 24 07975 g004
Table
Table 4. Differences and similarities between COVID-19 and severe sepsis bacterial infections.
Table 4. Differences and similarities between COVID-19 and severe sepsis bacterial infections.
COVID-19 InfectionSevere Sepsis Due to Bacterial Infections
Activation of platelets++++++++
Activation of leukocytes++++++
Tissue factor generation +++++++++
Cytokine generation+++++++++
Lung injury++++++++
Organ failure excluding lung++++
Development of atheroma++++
Development of venous thrombosis +++++++
Fibrinolysis++++++
Table
Table 5. Differences and similarities between COVID-19 and severe sepsis bacterial infections.
Table 5. Differences and similarities between COVID-19 and severe sepsis bacterial infections.
COVID-19 InfectionSevere Sepsis Due to Bacterial Infections
Venous thromboembolismfrequentnot frequent
Arterial thrombosisrelatively frequentnot frequent
Mortality rateapproximately 2%20–45% in severe sepsis
Incidence of infectionmarkedly highrelatively high
Death numbermarkedly highrelatively high
Microangiopathypositivepositive
Coagulationmild or hypercoagulable stateshypercoagulable state
Fibrinolysishypofibrinolytic statehyperfibrinolytic state
DICnot frequentfrequent
DIC, disseminated intravascular coagulation; COVID-19, coronavirus disease 2019.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Wada, H.; Shiraki, K.; Shimpo, H.; Shimaoka, M.; Iba, T.; Suzuki-Inoue, K. Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019. Int. J. Mol. Sci. 2023, 24, 7975. https://doi.org/10.3390/ijms24097975

AMA Style

Wada H, Shiraki K, Shimpo H, Shimaoka M, Iba T, Suzuki-Inoue K. Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019. International Journal of Molecular Sciences. 2023; 24(9):7975. https://doi.org/10.3390/ijms24097975

Chicago/Turabian Style

Wada, Hideo, Katsuya Shiraki, Hideto Shimpo, Motomu Shimaoka, Toshiaki Iba, and Katsue Suzuki-Inoue. 2023. "Thrombotic Mechanism Involving Platelet Activation, Hypercoagulability and Hypofibrinolysis in Coronavirus Disease 2019" International Journal of Molecular Sciences 24, no. 9: 7975. https://doi.org/10.3390/ijms24097975

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop